Skip to main content

Advertisement

SpringerLink
Log in

Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia

II. Successful cloning and amplification of natural killer cells

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

Defective natural killer (NK) cell populations from patients with chronic myelogenous leukemia (CML), that reacted with both HNK-1+ and B73.1+ antibodies, were obtained by a flluorescence-activated cell sorter (FACS). These fractions, along with NK fractions from normal donors which reacted with both antibodies, were expanded as bulk cultures or clones by limiting dilution, for 4 weeks in the presence of 10% interleukin 2 (IL 2), human type AB plasma, and irradiated human allogeneic mononuclear cells. Successfully established clones from patients with CML, with lytic activity against autologous and more differentiated neoplastic granulocytes, were generated more efficiently from B73.1+ than from HNK-1+ subsets. However, there were no significant differences among the generations of B73.1+ and HNK-1+ clones for both patients and normal donors with lytic activity against NK susceptible K-562 targets. Fresh myeloblast preparations from a blast crisis were found to be more susceptible to lysis by IL 2-proliferative B73.1+ and HNK-1+ clones than were fresh myelocyte preparations from a chronic phase CML patient, which were lytically susceptible to only B73.1+ clones. B73.1+ and HNK-1+ subsets from CML patients demonstrated major histocompatibility complex nonrestricted killing, and showed the following predominant phenotypes: B73.1+T3+T8+ or B73.1+T3+T8− from B73.1+ subsets; and HNK-1−T3+T8+ (initially HNK-1+) from HNK-1+ subsets. In contrast, B73.1+ and HNK-1+ clones from normal donors showed the following predominant phenotypes: B73.1+T3−T8−; and HNK-1−T3−T8− or HNK-1−T3−T8+ (initially all HNK-1+). Short-term in vitro IL 2 or interferon treatment of fresh NK defective subsets from CML patients resulted in minimal cytotoxic augmentation. In contrast, defective NK cells from CML patients, whether HNK-1+ or B73.1+ subsets, proliferated with complete regeneration of cytolytic activity after a 3–4 week exposure to IL 2, but differed in phenotypic profiles as compared to those of normal donors. These observations imply that not only fresh defective NK cells but also the cytotoxically restored clones from CML patients are derived from different NK subsets and may represent undifferentiated forms of NK cells that may be arrested at an early stage of development by yet unknown mechanism(s). In vitro substantiation of autologous leukemia cell killing by IL 2-proliferative NK cell clones is encouraging and may allow for new in vivo immunotherapeutic modalities in CML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abo T, Balch CM (1981) A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK—1). J Immunol 127:1024

    Google Scholar 

  2. Abo T, Balch CM (1983) In vitro propagation of cultured human natural killer cells expressing the HNK-1 differentiation antigen and spontaneous cytotoxic function. Eur J Immunol 13:383

    Google Scholar 

  3. Brunda MJ, Rosenbaum D (1983) Modulation of murine natural killer cell activity in vitro and vivo by recombinant human interferons. Cancer Res 44:597

    Google Scholar 

  4. Christopher SH, Kuribayashi K, Kern DE, Gillis S (1981) Interleukin 2 augments natural killer cell activity. Nature 291:335

    Google Scholar 

  5. Dempsey RA, Dinarello CA, Mier JW, Rosenwasser LJ, Allegretta M, Brown TE, Parkinson DR (1982) The differential effects of human leukocytic pyrogen/lymphocyte-activating factor, T cell growth factors, and interferon on human natural killer activity. J Immunol 129:2504

    Google Scholar 

  6. Edwards BS, Hawkins MJ, Borden EC (1983) Correlation between in vitro and systemic effects of native and recombinant interferon on human natural killer cell cytotoxicity. J Biol Response Mod 2:409

    Google Scholar 

  7. Edwards BS, Hawkins MJ, Borden EC (1984) Comparative in vivo and in vitro activation of human natural killer cells by two recombinant interferons-gamma differing in antiviral activity. Cancer Res 44:3135

    Google Scholar 

  8. Fujimiya Y, Bakke A, Chang WC, Linker-Islaeri M, Udis B, Horwitz D, Pattengale PK (1986) Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (Leu 7) and B73.1 (Leu 11c). Int J Cancer 37:639

    Google Scholar 

  9. Gastle G, Niederwieser D, Marth C, Huber H, Egg D, Schuler G, Margrieter R, Braunsteiner H, Huber C (1984) Human large granular lymphocytes and their relationship to natural killer activity in various disease states. Blood 64:288

    Google Scholar 

  10. Gidlund M, Orn A, Pattengale PK, Jansson M, Wigzell H, Nilsson K (1981) Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292:848

    Google Scholar 

  11. Golightely MG, D'Amore P, Golub SH (1982) Studies on cytotoxicity generated in human mixed lymphocyte cultures. II. Natural killer-like cytotoxicity mediated by human lymphocytes with receptors for IgM. Cell Immunol 70:219

    Google Scholar 

  12. Grimm EA, Mazumder A, Zhang HA, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823

    Article  CAS  PubMed  Google Scholar 

  13. Gronovik KO, Anderson J, Alm G, Stern P (1983) T-cell growth factors contain activity that supports natural killer activity in vitro. Scand J Immunol 18:307

    Google Scholar 

  14. Herberman RB, Holden HT (1978) Natural cell-mediated immunity. Adv Cancer Res 27:305

    Google Scholar 

  15. Herzenberg LA, Herzenberg LA (1977) Analysis and separation using the fluorescence activated cell sorter (FACS). In: Weir DM (ed) Handbook of experimental immunology, vol 3. Blackwell Publications, Oxford, p 1

    Google Scholar 

  16. Itoh D, Tsuchikawa K, Awataguchi T, Shiiba K, Kumagai K (1983) A case of chronic lymphocytic leukemia with properties characteristic of natural killer cells. Blood 61:940

    Google Scholar 

  17. Jannossay G, Roberts MM, Capellaro D, Greaves MF, Francis GE (1978) Use of the fluorescence activated cell sorter in human leukemia. In: Knapp W, Holabar K, Wiock G (eds) Immunofluorescence and related staining techniques. Elservier/North Holland Biochemical Press, Amsterdam, p 111

    Google Scholar 

  18. Kasai M, Leclerc JC, MaVay-Boudreu L, Shen FH, Cantor H (1979) Direct evidence that NK cells in nonimmune cell populations prevent tumour growth in vivo. J Exp Med 149:1260

    Google Scholar 

  19. Kay NE, Zarling JM (1984) Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 63:305

    Google Scholar 

  20. Lanier LL, Benike CJ, Phillips JH, Engleman EG (1985) Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the leu 7 and leu 11 antigens. J Immunol 134:794

    Google Scholar 

  21. London L, Perussia B, Trinchieri G (1985) Induction of proliferation in vitro of resting human natural killer cells: expression of surface activation antigens. J Immunol 134:718

    Google Scholar 

  22. Lotzova E, McCredie KB, Maroun JA, Dicke KA, Freireich EJ (1979) Some studies on natural killer cells in man. Transplant Proc 11:1390

    Google Scholar 

  23. Lotzova E, Savary CA, Gutterman JU, Hersh EH (1982) Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-gamma. Cancer Res 42:2480

    Google Scholar 

  24. Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 45:321

    Google Scholar 

  25. Lozzio BB, Lozzio CB (1979) Properties and usefulness of the original K562 human myelogenous leukemia cell line. Leuk Res 3:363

    Google Scholar 

  26. Lozzio CB, Lozzio BB, Yang WK, Ichiki A, Bamberger EG (1976) Absence of T-derived lymphocyte markers in a myelogenous leukemia (Ph1+) cell line K562. Cancer Res 36:4657

    Google Scholar 

  27. Lozzio BB, Lozzio CB, Krauss S, Wust CJ (1977) Leukemia associated antigens detected by a nonhuman primate antiserum to a Ph1+ myelogenous leukemia cell line. Blood 50:115

    Google Scholar 

  28. Marks SM, Baltimore D, McCaffrey R (1978) Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic myelogenous leukemia. N Engl J Med 298:812

    Google Scholar 

  29. Mazumder A, Rosenberg SA (1984) Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159:495

    Google Scholar 

  30. Mule JJ, Shu S, Rosenberg SA (1985) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 135:646

    Google Scholar 

  31. Nowell PC, Hungerford DA (1960) Minute chromosome in human chronic granulocytic leukemia. Science 132:1497

    Google Scholar 

  32. Ortaldo JR, Oldham RK, Cannon GC, Herberman RB (1977) Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. J Natl Cancer Inst 59:77

    Google Scholar 

  33. Palutke M, Kaplan J, Hussain M, Kithier K, Tabaczka P, Mirchandani I, Tanenbaum D (1983) Natural killer and suppressor T-cell chronic lymphocytic leukemia. Blood 62:627

    Google Scholar 

  34. Pattengale PK, Gidlund M, Nilsson K, Sundstrom C, Orn A, Wigzell H (1981) Lysis of human B-lymphocyte-derived lymphoma/leukemia cells of established cell lines by interferon-activated natural killer (NK) cells. Int J Cancer 28:459

    Google Scholar 

  35. Pattengale PK, Sundstrom C, Yu AL, Levine A (1984) Lysis of fresh leukemic blasts by interferon-activated human natural killer cells. Nat Immunol Cell Growth Regul 3:165

    Google Scholar 

  36. Persussia B, Starr S, Abraham S, Fanning V, Trinchieri G (1983) Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol 130:2133

    Google Scholar 

  37. Perussia B, Acuto O, Terhorst C, Faust J, Lazarus R, Fanning V, Trinchieri G (1983) Human natural killer cells analysed by B73.1, a monoclonal antibody blocking Fc receptor function. J Immunol 130:2142

    Google Scholar 

  38. Platsoucas CD, Fernandes G, Gupta SL, Kempin S, Clarkson B, Good RA, Gupta S (1980) Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: augmentation by in vitro treatment with interferon. J Immunol 125:1216

    Google Scholar 

  39. Pross HF, Jonda M (1975) Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes. Clin Exp Immunol 21:226

    Google Scholar 

  40. Rowley JD (1973) A new consistent chromosome abnormality in chronic myelogenous leukemia identified by quinicrine fluorescence and German staining. Nature 343:290

    Google Scholar 

  41. Schmidt RE, Hercent T, Fox DA, Bensusan A, Bartley G, Daley JE, Schlossman SF, Reinherz EL, Ritz J (1985) The role of interleukin 2 and T 11 E rosette antigen in activation and proliferation of human NK clones. J Immunol 135:672

    Google Scholar 

  42. Stainhauer EH, Doyle AT, Kadish AS (1985) Human natural killer cytotoxic factor (NKCF): role of IFN-gamma. J Immunol 133:714

    Google Scholar 

  43. Svedersky LP, Shepard HM, Spencer SA, Shalady MR, Palladin MA (1984) Augmentation of human natural killer-mediated cytotoxicity by recombinant human interleukin 2. J Immunol 133:714

    Google Scholar 

  44. Timonens T, Ortald JR, Herberman RB (1981) Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med 153:569

    Google Scholar 

  45. Timonen T, Ortaldo JR, Stadler BU, Bonnard GD, Sharrow SO, Herberman RB (1982) Cultures of purified human natural killer cells: growth in the presence of IL-2. Cell Immunol 72:178

    Google Scholar 

  46. Ting CC, Yang SY, Hargrove ME (1982) Effect of interleukin 2 on cytotoxic effectors. II. Long-term culture of NK cells. Cell Immunol 73:279

    Google Scholar 

  47. Toten M, Sidell N, Golub SH (1982) Interleukin 2 and stimulator lymphoid cells induce thymocytes to bind and kill K562 targets. J Exp Med 156:1545

    Google Scholar 

  48. Trinchieri G, Santoli D, Grano D, Perussia B (1981) Antagonistic effects of interferons on the cytotoxicity mediated by natural killer cells. Fed Proc 40:2705

    Google Scholar 

  49. Van de Griend RJ, Bolhuis RLH (1985) In vitro expansion and analysis of cloned cytotoxic T cells derived from patients with chronic T gammalymphoproliferative disorders. Blood 65:1002

    Google Scholar 

  50. Van de Griend RJ, Van Krimpken BA, Ronteltap GPM, Bolhuis RLH (1984) Rapidly expanded human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non gamma, or null cells. J Immunol 132:3185

    Google Scholar 

  51. Vose BM (1981a) Expansion of autorecognitive cytotoxic effectors in human cancer by T cell growth factor (interleukin 2). Arch Geschwulstforsch 51:317

    Google Scholar 

  52. Vose BM, Moore M (1981b) Cultured human T-cell lines kill autologous solid tumours. Immunol Lett 3:237

    Google Scholar 

  53. Vose Bm, Bonnard GD (1983b) Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. I. The effect of lectin on the proliferative frequency and cytotoxic activity of cultured lymphoid cells. J Immunol 130:687

    Google Scholar 

  54. Warner JF, Dennert G (1982) Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastases in vivo. Nature 300:31

    Google Scholar 

  55. Ziegler HW, Kay NE, Zarling JM (1981) Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 27:321

    Google Scholar 

Download references

Author information

Author notes

  1. Yoshiaki Fujimiya

    Present address: Department of Human Oncology, University of Wisconsin Clinical Cancer Center, 53792, Madison, WI, USA

  2. Anthony Bakke

    Present address: Department of Clinical Pathology, Oregon Health Sciences University, 97201, Portland, OR, USA

Authors and Affiliations

  1. Department of Pathology, University of Southern California School of Medicine, 90033, Los Angeles, CA, USA

    Yoshiaki Fujimiya, Weng-Cheng Chang & Paul K. Pattengale

  2. Department of Internal Medicine, University of Southern California School of Medicine, 90033, Los Angeles, CA, USA

    Anthony Bakke & David Horwitz

Authors
  1. Yoshiaki Fujimiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weng-Cheng Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony Bakke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Horwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul K. Pattengale
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fujimiya, Y., Chang, WC., Bakke, A. et al. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. Cancer Immunol Immunother 24, 213–220 (1987). https://doi.org/10.1007/BF00205632

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00205632

Keywords

Search

Navigation